Gabelli Funds LLC Cytokinetics Inc Transaction History
Gabelli Funds LLC
- $12.3 Billion
- Q4 2024
A detailed history of Gabelli Funds LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Gabelli Funds LLC holds 5,000 shares of CYTK stock, worth $202,150. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,000
Previous 5,400
7.41%
Holding current value
$202,150
Previous $285,000
17.54%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CYTK
# of Institutions
400Shares Held
115MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$593 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$482 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$435 Million0.31% of portfolio
-
State Street Corp Boston, MA6.17MShares$249 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.84MShares$115 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.81B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...